Break it Down: Dimerix inks major Japanese partnership

Fraser Palamara details Dimerix’s deal with Japanese pharmaceutical company FUSO to fight a deadly kidney disease.

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, Fraser Palamara tells all on Dimerix's (ASX:DXB) new partner in Japan’s FUSO Pharmaceutical Industries to develop a drug candidate in fighting kidney disease.

FUSO will be funding clinical trials in Japan and Dimerix will receive more than equivalent of A$170 million as upfront payment and in sales milestones.

Tune in to get the latest.

While Dimerix is a Stockhead advertiser, it did not sponsor this content.

Originally published as Break it Down: Dimerix inks major Japanese partnership